HRCM
KRYS icon

Hood River Capital Management’s Krystal Biotech KRYS Stock Holding History

Hood River Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247M Buy
663,375
+43,789
+7% +$13.1M 1.79% 9
2026
Q1 		$160M Buy
619,586
+6,284
+1% +$1.67M 1.6% 13
2025
Q4 		$151M Buy
613,302
+6,356
+1% +$1.34M 1.66% 11
2025
Q3 		$107M Buy
606,946
+73,923
+14% +$11.1M 1.27% 24
2025
Q2 		$73.3M Buy
533,023
+8,379
+2% +$1.23M 1.02% 35
2025
Q1 		$94.6M Buy
524,644
+11,918
+2% +$2M 1.61% 12
2024
Q4 		$80.3M Buy
512,726
+10,622
+2% +$1.88M 1.19% 28
2024
Q3 		$91.4M Sell
502,104
-18,989
-4% -$3.66M 1.48% 17
2024
Q2 		$95.7M Buy
521,093
+25,507
+5% +$4.28M 1.98% 9
2024
Q1 		$88.2M Buy
495,586
+37,073
+8% +$5.15M 1.97% 11
2023
Q4 		$56.9M Sell
458,513
-1,976
-0.4% -$219K 1.56% 18
2023
Q3 		$53.4M Buy
460,489
+8,033
+2% +$980K 1.71% 15
2023
Q2 		$53.1M Buy
452,456
+5,063
+1% +$517K 1.58% 22
2023
Q1 		$35.8M Buy
447,393
+20,514
+5% +$1.61M 1.16% 38
2022
Q4 		$33.8M Buy
426,879
+10,123
+2% +$751K 1.23% 32
2022
Q3 		$29M Buy
416,756
+7,745
+2% +$560K 1.11% 33
2022
Q2 		$26.9M Buy
409,011
+24,201
+6% +$1.51M 1.07% 36
2022
Q1 		$25.6M Buy
384,810
+159,083
+70% +$9.93M 0.85% 43
2021
Q4 		$15.8M Sell
225,727
-174
-0.1% -$10.1K 0.47% 68
2021
Q3 		$11.8M Sell
225,901
-8,866
-4% -$525K 0.36% 76
2021
Q2 		$16M Sell
234,767
-3,115
-1% -$217K 0.48% 73
2021
Q1 		$18.3M Sell
237,882
-23,240
-9% -$1.69M 0.59% 68
2020
Q4 		$15.7M Buy
261,122
+3,919
+2% +$196K 0.52% 77
2020
Q3 		$11.1M Sell
257,203
-25,008
-9% -$1.09M 0.48% 77
2020
Q2 		$11.7M Buy
+282,211
New +$13.6M 0.52% 76

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hood River Capital Management's KRYS Position: Q2 2026 in Review

Hood River Capital Management increased its Krystal Biotech (KRYS) stake by 7.1% in Q2 2026, buying an estimated $13.1M and bringing the position to 663,375 shares worth $247M. The position accounts for 1.79% of the portfolio, ranked #9.

Hood River Capital Management first reported a position in KRYS in Q2 2020 and has held it in 25 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Hood River Capital Management held 663,375 shares of Krystal Biotech worth $247M as of Q2 2026.
  • Hood River Capital Management bought 43,789 Krystal Biotech shares in Q2 2026, an estimated $13.1M.
  • Krystal Biotech made up 1.79% of Hood River Capital Management's portfolio in Q2 2026, its #9 holding.
  • Hood River Capital Management first reported a position in Krystal Biotech in Q2 2020 and has held it in 25 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Hood River Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.